2017 Pharma by numbers

June 17, 2014

Annual spending by the pharmaceutical industry is 5.5 times greater than the defence and aerospace industries 5 of the 11 leading global R&D firms were research-based pharmaceutical companies In 2014, pharmaceutical industry gross value added was USD 452.8 billion industry value added is almost the same size as the economy of Argentina The global pharmaceutical industry employed over 5 million people and paid USD 97.2 billion in salaries in 2014 (including generics).

Spotlight

Hovione

Hovione has over 57 years of experience as a CDMO and is currently a fully integrated supplier offering from drug substance to drug product intermediate to drug product. With four FDA inspected sites, USA, China, Ireland and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, Hovione provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds. For generic pharmaceutical customers, the company offers niche off-patent API products. Hovione also provides proprietary product development and licensing opportunities for drug products.

OTHER WHITEPAPERS
news image

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

whitePaper | December 20, 2022

Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry.

Read More
news image

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | October 14, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embarking on a new drug development project.

Read More
news image

Pharma R&D Annual Review 2022 Navigating the Landscape

whitePaper | May 7, 2022

Citeline, Welcome to Pharmaprojects' 2022 reviews of trends in pharmaceutical R&D. Take a look at the evolution of pharma R&D and in this article, examine the state of play at the start of 2022.

Read More
news image

Regenerative Medicine

whitePaper | September 16, 2022

T wice a year, we survey the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to our members.

Read More
news image

Helping Patients Find and Engage with Clinical Trials

whitePaper | June 16, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible

Read More
news image

How purpose-built tech can help pharmaceutical and life science companies streamline healthcare provider interactions

whitePaper | December 15, 2022

In today’s hypercompetitive pharmaceutical and life sciences (PLS) industry, strategic partnerships are more critical than ever. A smaller life sciences company may have relationships with hundreds of healthcare providers and healthcare organizations.

Read More

Spotlight

Hovione

Hovione has over 57 years of experience as a CDMO and is currently a fully integrated supplier offering from drug substance to drug product intermediate to drug product. With four FDA inspected sites, USA, China, Ireland and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, Hovione provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds. For generic pharmaceutical customers, the company offers niche off-patent API products. Hovione also provides proprietary product development and licensing opportunities for drug products.

Events